{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:38:34Z","timestamp":1792291114122,"version":"4.4.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Gastroenterolog\u00eda de M\u00e9xico"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.rgmx.2020.10.001","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T08:38:40Z","timestamp":1608885520000},"page":"70-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Segundo Consenso Mexicano de terapia biol\u00f3gica y mol\u00e9culas peque\u00f1as en enfermedad inflamatoria intestinal"],"prefix":"10.1016","volume":"86","author":[{"given":"J.K.","family":"Yamamoto-Furusho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J.","family":"Bosques-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Mart\u00ednez-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rgmx.2020.10.001_bib0495","first-page":"46","article-title":"Diagn\u00f3stico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation","volume":"82","author":"Yamamoto-Furusho","year":"2017","journal-title":"Rev Gastroenterol Mex"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0500","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/flgastro-2018-101054","article-title":"Recent advances in monoclonal antibody therapy in IBD: Practical issues","volume":"10","author":"Tamilarasan","year":"2019","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0505","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MOG.0000000000000444","article-title":"Inflammatory bowel disease therapy: Blockade of cytokines and cytokine signaling pathways","volume":"34","author":"Yamamoto-Furusho","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0510","first-page":"263","article-title":"Grupo mexicano de Consenso del uso de agentes anti-TNF-\u03b1 en EII - Mexican Consensus on the use of agents anti-TNF-alpha in the treatment of inflammatory bowel disease","volume":"74","author":"Yamamoto-Furusho","year":"2009","journal-title":"Rev Gastroenterol Mex"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0515","first-page":"417","article-title":"Sistema GRADE para clasificar nivel de evidencia y grado de las recomendaciones para la elaboraci\u00f3n de gu\u00edas de buena pr\u00e1ctica cl\u00ednica","volume":"77","author":"O\u00f1ate-Oca\u00f1a","year":"2009","journal-title":"Cir Ciru"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0520","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1155\/2014\/792386","article-title":"Patient-reported outcome measures in inflammatory bowel disease","volume":"28","author":"El-Matary","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0525","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.cgh.2017.10.019","article-title":"Patient-reported outcome measures for use in clinical trials and clinical practice in inflammatory bowel diseases: A systematic review","volume":"16","author":"De Jong","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.rgmx.2020.10.001_bib0530","first-page":"S576","article-title":"Patient Reported Outcome Measures (PROMs) in inflammatory bowel disease: New data","volume":"11","author":"Bojic","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0535","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.crohns.2011.05.003","article-title":"C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis","volume":"5","author":"Turner","year":"2011","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0540","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3892\/mmr.2014.2180","article-title":"Fecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome","volume":"10","author":"Chang","year":"2014","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0545","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ajg.2015.6","article-title":"A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS","volume":"110","author":"Menees","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0550","first-page":"41","article-title":"Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50years","volume":"9","author":"Kennedy","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0555","doi-asserted-by":"crossref","first-page":"e0212404","DOI":"10.1371\/journal.pone.0212404","article-title":"Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease","volume":"14","author":"Sagami","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0560","first-page":"77","article-title":"Faecal calprotectin","volume":"39","author":"Pathirana","year":"2018","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0565","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MEG.0000000000000761","article-title":"The natural history of Crohn's disease in children: a review of population-based studies","volume":"29","author":"Duricova","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0570","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjw116","article-title":"Predicting outcomes to optimize disease management in inflammatory bowel diseases","volume":"10","author":"Torres","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0575","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/ajg.2012.117","article-title":"Development of the Paris definition of early Crohn's disease for disease-modification trials: Results of an international expert opinion process","volume":"107","author":"Peyrin-Biroulet","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0580","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0585","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): A multicentre, randomised, controlled phase3 trial","volume":"390","author":"Colombel","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0590","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/apt.13353","article-title":"Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients \u2014 a POCER study analysis","volume":"42","author":"De Cruz","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756284818785571","article-title":"Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn's disease: Systematic review and meta-analysis","volume":"11","author":"Tham","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0600","article-title":"Development and validation of a clinical decision support tool that incorporates pharmacokinetic data to predict endoscopic healing in patients treated with infliximab","author":"Casteele","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0605","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0610","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0615","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0620","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrgastro.2013.253","article-title":"Tailoring anti-TNF therapy in IBD: Drug levels and disease activity","volume":"11","author":"Ben-Horin","year":"2014","journal-title":"Nat Rev Gastroenterol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0625","first-page":"197","article-title":"Pharmacogenetics in inflammatory bowel disease: Understanding treatment response and personalizing therapeutic strategies","volume":"10","author":"Yamamoto-Furusho","year":"2017","journal-title":"Pharmacogenomics Pers Med"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0630","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.3748\/wjg.v20.i17.5031","article-title":"Utility of serum TNF-\u03b1, infliximab trough level, and antibody titers in inflammatory bowel disease","volume":"20","author":"Pallagi-Kunst\u00e1r","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0635","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0640","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0645","article-title":"Effect of a practice-wide anti-TNF proactive therapeutic drug monitoring program on outcomes in pediatric patients with inflammatory bowel disease","author":"Lyles","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0650","article-title":"Favorable outcomes and anti-TNF durability after addition of an immunomodulator for anti-drug antibodies in pediatric IBD patients","author":"Colman","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0655","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/apt.13990","article-title":"Systematic review with meta-analysis: The efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-\u03b1 agent (infliximab), in inflammatory bowel diseases","volume":"45","author":"Komaki","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0660","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00384-019-03354-7","article-title":"An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease","volume":"34","author":"Ebada","year":"2019","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0665","first-page":"414","article-title":"Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico","volume":"83","author":"Mayoral-Zavala","year":"2018","journal-title":"Rev Gastroenterol Mex"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0670","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s10620-018-5202-5","article-title":"Maintenance adalimumab concentrations are associated with biochemical, endoscopic, and histologic remission in inflammatory bowel disease","volume":"63","author":"Juncadella","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0675","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ibd\/izy044","article-title":"Therapeutic drug monitoring guides the management of Crohn's patients with secondary loss of response to adalimumab","volume":"24","author":"Restellini","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0680","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0685","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.crohns.2012.03.018","article-title":"Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients","volume":"7","author":"Baert","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0690","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/ibd\/izx103","article-title":"Incidence and predictors of success of adalimumab dose escalation and de-escalation in ulcerative colitis: A Real-World Belgian Cohort Study","volume":"24","author":"De Vondel","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0695","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0700","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0705","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/MIB.0000000000001144","article-title":"Clinical outcomes of golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis","volume":"23","author":"Taxonera","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0710","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/ibd\/izy178","article-title":"Treatment failure of TNF-\u03b1 inhibitors in obese patients with inflammatory bowel disease\u2014A cohort study","volume":"24","author":"Madsen","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0715","article-title":"Associations between obesity and the effectiveness of anti-tumor necrosis factor-\u03b1 agents in inflammatory bowel disease patients: A literature review and meta-analysis","volume":"19","author":"Dai","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0720","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14740338.2017.1300251","article-title":"The safety of vedolizumab for the treatment of ulcerative colitis","volume":"16","author":"Novak","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0725","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/MIB.0000000000001067","article-title":"Novel insights into the mechanisms of gut homing and antiadhesion therapies in inflammatory bowel diseases","volume":"23","author":"Zundler","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0730","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0735","first-page":"400","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0740","first-page":"144","article-title":"The Mexican Consensus on the Diagnosis and Treatment of Ulcerative Colitis","volume":"83","author":"Yamamoto-Furusho","year":"2018","journal-title":"Rev Gastroenterol Mex"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0745","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0750","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0755","first-page":"412","article-title":"Long-term efficacy of vedolizumab for Crohn's disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0760","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"NEJM"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0765","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0770","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1053\/j.gastro.2017.03.038","article-title":"Ustekinumab for Crohn's disease","volume":"152","author":"Khanna","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0775","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0780","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MOG.0000000000000444","article-title":"Inflammatory bowel disease therapy: Blockade of cytokines and cytokine signaling pathways","volume":"34","author":"Yamamoto-Furusho","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0785","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0790","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0795","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0800","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitisB: AASLD 2018 hepatitisB guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0805","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitisB virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0810","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","article-title":"Management of patients with hepatitisB who require immunosuppressive therapy","volume":"11","author":"Hwang","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0815","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitisB virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0820","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1002\/ibd.22950","article-title":"Varicella zoster virus infection in inflammatory bowel disease","volume":"18","author":"Cullen","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0825","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0830","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG Clinical Guideline: Preventive care in inflammatory bowel disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0835","unstructured":"CDC. 4. Contraindications and Precautions. General Best Practice Guidelines for Immunization: Contraindications and Precautions. 2019 [consultado 19 Sep 2019]. Disponible en: https:\/\/www.cdc.gov\/vaccines\/hcp\/aciprecs\/generalrecs\/contraindications.html"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0840","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1016\/j.vaccine.2017.05.069","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017 \u2014 Recommendations","volume":"35","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0845","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1365-2036.2009.03973.x","article-title":"Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine","volume":"29","author":"Seksik","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0850","first-page":"300","article-title":"Use of 9-Valent Human Papillomavirus (HPV) vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"Morb Mortal Wkly Rep Use"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0855","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M18-3600","article-title":"Recommended adult immunization schedule. United States, 2019","volume":"170","author":"Kim","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0860","doi-asserted-by":"crossref","first-page":"112","DOI":"10.15585\/mmwr.mm6805a4","article-title":"Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger \u2014 United States, 2019","volume":"68","author":"Robinson","year":"2019","journal-title":"Morb Mortal Wkly Rep Advis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0865","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaut.2017.03.011","article-title":"Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis","volume":"80","author":"Lopez","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0870","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ibd\/izx101","article-title":"Immunogenicity of quadrivalent influenza vaccine for patients with inflammatory bowel disease undergoing immunosuppressive therapy","volume":"24","author":"Shirai","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0875","first-page":"593","article-title":"Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: A randomized clinical trial","volume":"26","author":"Caldera","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0880","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/jgh.14832","article-title":"Incidence and risk factors of Pneumocystis jirovecii pneumonia in Korean patients","volume":"35","author":"Nam","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0885","first-page":"167","article-title":"Risk factors for mortality in Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease","volume":"56","author":"Yoshida","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0890","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.cgh.2017.06.020","article-title":"Risk of pneumonia caused by Pneumocystis jirovecii in inflammatory bowel disease: The role of concomitant pulmonary comorbidities","volume":"17","author":"Macaluso","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0895","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0900","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/ajg.2012.406","article-title":"Increased risk of pneumonia among patients with inflammatory bowel disease","volume":"108","author":"Long","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0905","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ibd.21800","article-title":"Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease","volume":"18","author":"Fiorino","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0910","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.dld.2017.09.002","article-title":"Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients","volume":"49","author":"Abreu","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0915","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/ecco-jcc\/jjw109","article-title":"Asymptomatic parasitic infection in a Crohn's disease patient on anti-TNF \u03b1 therapy: An alert for our patients?","volume":"10","author":"Cocca","year":"2016","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0920","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14740338.2017.1300251","article-title":"The safety of vedolizumab for the treatment of ulcerative colitis","volume":"16","author":"Novak","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0925","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0930","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MIB.0000000000001049","article-title":"Risk for overall infection with anti-TNF and anti-integrin agents used in IBD: A systematic review and meta-analysis","volume":"23","author":"Shah","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0935","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world pattern of biologic use in patients with inflammatory bowel disease: Treatment persistence, switching, and importance of concurrent immunosuppressive therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0940","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/apt.12037","article-title":"Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-\u03b1 inhibitors","volume":"36","author":"Papay","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0945","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0950","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: A systematic review and meta-analysis of randomised controlled trials","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0955","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/BTT.S150958","article-title":"The conundrum of indeterminate QuantiFERON- TB Gold results before anti-tumor necrosis factor initiation","volume":"12","author":"Hakimian","year":"2018","journal-title":"Biol Targets Ther"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0960","article-title":"Tofacitinib for the treatment of moderately to severely active ulcerative colitis: A systematic review, network meta-analysis and economic evaluation","author":"Lohan","year":"2020","journal-title":"BMJ Open Gastro"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0965","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5217\/ir.2019.00026","article-title":"Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia","volume":"17","author":"Ooi","year":"2019","journal-title":"Intest Res"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0970","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2017-211322","article-title":"Reactivation of hepatitisB virus infection in patients with rheumatoid arthritis receiving tofacitinib: A real-world study","volume":"77","author":"Chen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0975","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rgmx.2020.10.001_bib0980","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2217\/imt-2018-0113","article-title":"Tuberculosis, hepatitisB and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis","volume":"11","author":"Zhang","year":"2019","journal-title":"Immunotherapy"}],"container-title":["Revista de Gastroenterolog\u00eda de M\u00e9xico"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0375090620301324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0375090620301324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:46:49Z","timestamp":1759812409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0375090620301324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0375090620301324"],"URL":"https:\/\/doi.org\/10.1016\/j.rgmx.2020.10.001","relation":{},"ISSN":["0375-0906"],"issn-type":[{"value":"0375-0906","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Segundo Consenso Mexicano de terapia biol\u00f3gica y mol\u00e9culas peque\u00f1as en enfermedad inflamatoria intestinal","name":"articletitle","label":"Article Title"},{"value":"Revista de Gastroenterolog\u00eda de M\u00e9xico","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rgmx.2020.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Asociaci\u00f3n Mexicana de Gastroenterolog\u00eda. Published by Masson Doyma M\u00e9xico S.A.","name":"copyright","label":"Copyright"}]}}